Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment - PubMed (original) (raw)

Review

Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment

Paul A Lapchak. Curr Neurol Neurosci Rep. 2002 Jan.

Abstract

Hemorrhagic transformation (HT) is a frequent consequence of ischemic stroke that becomes more prevalent after thrombolytic therapy. Despite concerns about safety parameters, thrombolytic drugs remain the first course of action available to clinicians for stroke management. However, recent efforts in preclinical studies have attempted to discover other drugs that can lessen the risk of hemorrhage associated with thrombolytic administration. This review focuses on three classes of pharmacologic agents that have shown some promise in animal models of stroke, and can thus be considered as possible candidates for coadministration with thrombolytics in the treatment of stroke. These include the following: 1) spin trap agents, such as alpha-phenyl-N-t-butylnitrone (PBN) that scavenge free radicals; 2) matrix metalloproteinase (MMP) inhibitors, such as BB-94, that prevent membrane and vessel remodeling following ischemia; and 3) the novel glycoprotein (GP) IIb/IIIa platelet receptor antagonist SM-20302. Although these drugs affect different mechanisms, the common denominator seemed to be their effectiveness in reducing the incidence of hemorrhage in response to thrombolytic infusion following an embolic stroke.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Proc Soc Exp Biol Med. 1999 Dec;222(3):236-45 - PubMed
    1. J Exp Med. 1985 Dec 1;162(6):2163-8 - PubMed
    1. Brain Res. 1998 Jun 8;795(1-2):63-70 - PubMed
    1. Neurosurgery. 1998 Dec;43(6):1382-96; discussion 1396-7 - PubMed
    1. Am J Physiol. 1997 Apr;272(4 Pt 2):H1986-95 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources